NCT06532058 - Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

February 10, 2025

Study Completion Date

May 10, 2025

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)

Interventions

DRUG

QHRD107 capsule，Venclexta and Azacitidine

QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）

Trial Locations (10)

RECRUITING

ShengJing Hospital, Shenyang

RECRUITING

Tongren Hospital Shanghai Jiao Tong University School Of Medicine, Shanghai

RECRUITING

Ruijin hospitol, Shanghai

RECRUITING

Zhongda Hospital, Nanjing

RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

The First People's Hospital of Changzhou, Changzhou

RECRUITING

Huai 'an First People's Hospital, Huaian

RECRUITING

Qilu Hospital of Shandong University, Jinan

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

RECRUITING

Henan Cancer Hospital, Zhengzhou